Protagenic Therapeutics, Inc.
21.3.2024 13:43:15 CET | ACCESS Newswire | Press release
NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid price of shares of PTIX has remained above $1.00 per share for ten consecutive trading days. This resolves the issue of potential delisting from Nasdaq by May 19, 2024 that the company had been facing.
On Tuesday, November 21, 2023, the company received a deficiency letter from Nasdaq stating that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, because it had not maintained a minimum bid price of $1.00 per share for 30 consecutive trading days. The Notification Letter stated that the company had 180 calendar days, or until May 19, 2024, to regain compliance by having a closing bid price of at least $1.00 per share for ten consecutive trading days. On March 19, 2024, the company received a formal notice from Nasdaq confirming that it has regained compliance with Listing Rule 5550(a)(2).
About Protagenic Therapeutics, Inc.:
Protagenic Therapeutics, Inc. (Nasdaq: PTIX) is committed to pioneering neuro-active peptides into therapeutics to mitigate stress-related disorders. For more information, visit www.protagenic.com.
About PT00114:
PT00114, a 41-amino-acid synthetic peptide, holds promise in treating various neuro-psychiatric conditions, including depression, anxiety, and PTSD. It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels.
Forward-Looking Statements:
This press release contains forward-looking statements concerning Protagenic Therapeutics' product candidates and clinical trial plans. These statements are subject to various risks and uncertainties. Investors are urged to exercise caution and not place undue reliance on these forward-looking statements.
Company Contact:
Alexander K. Arrow, MD, CFA Chief Financial Officer Protagenic Therapeutics, Inc. 149 Fifth Ave, Suite 500, New York, NY 10010. Tel: 213-260-4342 Email: alex.arrow@protagenic.com
Investor Relations Contact:
Kirin M. Smith, President, PCG Advisory, Inc. 950 Third Avenue, Suite #2700, New York, NY 10022. Tel: 646-823-8656 Email: ksmith@pcgadvisory.com
SOURCE: Protagenic Therapeutics, Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Aminona Capital Partners Closed Second Latam Real Estate Fund11.5.2026 14:55:00 CEST | Press release
ZURICH, SWITZERLAND / ACCESS Newswire / May 11, 2026 / Aminona Capital Partners have successfully advised and partnered on closing a second South and Central America residential and commercial real estate fund which specifically targets large scale real estate opportunities in the region. Co-founders Nicolas Jenik and Phillip Morelle are very optimistic about the real estate prospects in Latin America, specifically in countries such as Argentina, Chile, Colombia and Venezuela which are already showing large returns and projected to continue growing. With a vast network on the ground in the region and deep knowledge of market dynamics in the Latin American real estate sector, Aminona Capital Partners are able to bring added value to investors and maximising returns. The plan is now to roll out a third real estate fund in the near future targeting the same region using the same opportunity driven strategy of pursing added value transactions, development repositioning, well financed const
Frame Security Launches with $50M to Build the Future of Human Security11.5.2026 14:05:00 CEST | Press release
Backed by Index Ventures, Team8, and Picture Capital, Frame is launching an AI-driven platform designed to help organizations defend against the growing wave of AI-powered social engineering and deepfake attacks by empowering employees to be the strongest line of defense NEW YORK CITY, NY / ACCESS Newswire / May 11, 2026 / Frame Security, today announced its public launch alongside a $50 million funding round led by Index Ventures, Team8, and Picture Capital, with participation from industry heavyweights Wiz CEO Assaf Rappaport and Elad Gil, who initially joined as an angel investor and has since doubled down through his fund, Gil Capital. The company is building a new category of human risk security, designed to protect organizations against the largest attack vector in cybersecurity: people. Nearly 96% of organizations provide some form of security awareness training, yet roughly 90% of data breaches still involve the human element. As a result, organizations are investing heavily in
TruMerit and Credivera Issue First Verifiable Digital Credentials for Global Healthcare Professionals8.5.2026 16:00:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / May 8, 2026 / TruMerit, a global leader in healthcare workforce development and credential verification, today announced that it has issued its first verifiable digital credentials to healthcare professionals through a new partnership with Credivera, marking a major step forward in secure, portable credential verification for the global healthcare workforce. The first group of digital credentials has been awarded to nurses and other healthcare professionals who successfully passed TruMerit's global certification examinations over the last year. These include the Certified Global Nurse credential and credentials tailored for nurses and other healthcare workers specializing in rehabilitation care. These secure credentials can now be stored, managed, and shared digitally, allowing employers, regulators, and licensing authorities to instantly verify professional qualifications. Through Credivera's secure credential exchange platform, TruMerit credential
MicroVision and Avular Collaborate to Advance Autonomous Sensing and Drone Integration for Next-Generation Infrastructure Applications7.5.2026 22:05:00 CEST | Press release
Integrated lidar and modular drone platforms enable scalable autonomy, mapping, and navigation across complex real-world environments REDMOND, WA AND EINDHOVEN, THE NETHERLANDS / ACCESS Newswire / May 7, 2026 / MicroVision, Inc., (Nasdaq:MVIS), a leader in advanced perception solutions, today announced the signing of a Memorandum of Understanding (MoU) with Avular Innovations B.V. to integrate their technologies and accelerate the development of next-generation autonomous systems for civil infrastructure and global commercial applications. By combining MicroVision's high-performance, solid-state lidar, optimized for reduced energy usage and increased operational efficiency, with Avular's modular drone platforms and system integration expertise, the companies are creating a flexible, scalable solution designed to address real-world operational challenges across global markets. The collaboration focuses on delivering advanced capabilities, including autonomous mission execution in GPS-de
Innodata Reports Record First Quarter 2026 Results7.5.2026 22:05:00 CEST | Press release
Revenue Up 54% Year-Over-Year, Beats Consensus by 18% Adjusted EBITDA of $25.0 Million Beats Consensus by 139%; Adjusted Gross Margin Expands to 47% Raises Full-Year 2026 Revenue Growth Guidance to ~40% or More, Up From ~35% or More Announces New Engagements With Big Tech Company Expected to Generate Approximately $51 Million of Revenue in 2026 NEW YORK, NY / ACCESS Newswire / May 7, 2026 / INNODATA INC. (Nasdaq:INOD) today reported results for the first quarter ended March 31, 2026. Revenue of $90.1 million, representing 54% year-over-year revenue growth. Adjusted Gross Profit of $42.6 million, representing Adjusted Gross Margin of 47%.* Adjusted EBITDA of $25.0 million, or 28% of revenue, an increase of $12.3 million from $12.7 million in the same period last year.* Net income of $14.9 million, or $0.46 per basic share and $0.42 per diluted share, compared to net income of $7.8 million, or $0.25 per basic share and $0.22 per diluted share, in the same period last year. Cash, cash equ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom